Nepal company to buy 2 million shots of Globe Biotech's Covid-19 vaccine
Published : Thursday, 22 October, 2020 at 9:37 PM Count : 474
A Nepalese company has placed order to buy two million shots of vaccine developed by Bangladeshi company Globe Biotech Ltd after it passes trials, said the company officials on Thursday.
Anmol Healthcare Ltd, the Nepalese company, has informed Globe Biotech Ltd of their demand through a letter of intent on Wednesday, said Ambassador of Nepal to Bangladesh Dr Banshidhar Mishra.
The Nepalese ambassador visited Globe Biotech Ltd corporate office in Dhaka on Thursday where he reached an agreement to buy the shots of Globe Biotech's vaccine BANCOVID while talking to Globe Biotech's chairman Harunur Rashid.
"Anmol Healthcare Ltd sent the letter of intent to us via email and we have already replied them that we will supply our vaccines once it will pass the trials," he said.
The Nepalese ambassador also spoke to journalists following his visit and the ambassador said his country will buy BANCOVID "for sure" if the vaccine passes clinical trials.
"We anticipate that this vaccine will be cheaper. Another reason is the virus strain in South Asia which causing infection are the same—in Bangladesh and Nepal---so this vaccine will be more effective for our country," Dr Banshidhar Mishra said adding that his government is also exploring other sources of vaccine.
Addressing the journalists, Harunur Rashid said, "We'll export our vaccine meeting the demand of Bangladesh. Apart from Nepal, we've already received an order from another country to export 20 million shots."
Dr Banshidhar Mishra said: "As a physician I have learned details about the vaccine of Globe Biotech. It is completely their own invention. We are ready to buy this vaccine. If they are successful, we can also purchase on G2G system. If the Bangladesh government wants, we will also take part in the trial of the vaccine."
The World Health Organisation (WHO) has listed the Covid-19 vaccine developed by Globe Biotech.
Globe's vaccine was listed on the WHO's draft landscape of Covid-19 candidate vaccines on 15 October.
According to the WHO's draft list of possible vaccines for the novel coronavirus, 198 different vaccines are being developed in various countries.
Of the vaccines, 156 have been going through a preclinical evaluation and 42 others a clinical evaluation. Ten of them have been undergoing Phase 3 trials which are the late-stage clinical trials and determine both the efficacy and safety of the vaccine.
Novavax, Johnson & Johnson, Moderna, Pfizer AstraZeneca, Sinovac, Sinopharm, and the Murdoch Children's Research Institute have been ahead in the race for final approval for their vaccines.
The candidature of the Globe Biotech vaccine has been shown on the WHO list as a DNA plasmid type vaccine at the preclinical stage.
Globe Biotech is the only company, globally, to be listed with three vaccine candidates – DNA plasmid vaccine, Adenovirus Type 5 Vector and D614G variant LNP-encapsulated mRNA.
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) announced it would hold a human trial of BANCOVID, a Covid-19 vaccine developed by Globe Biotech.
icddr,b also signed a memorandum of understanding with the company to conduct the trial.
On 2 July, Globe Biotech announced it was developing a Covid-19 vaccine as it had completed preliminary animal trials successfully.
On 5 October, Globe Biotech said they had received "very promising" results from the pre-clinical trials on rabbits and mice.
The company said BANCOVID would hit the market in late December or early January next year if the government is fully supportive.